Oncology and Autoimmune Diseases

B2067

Indications ——NMOSD and other autoimmune diseases

资源 30

Research progress
Pre-clinical research

Potential Advantages

(1) Neuromyelitis optica spectrum disorder, also known as neuromyelitis optica (NMO), is a condition arising from complement system reactions caused by NMO-IgG; it causes inflammatory response of the central nervous system and demyelination representative of nerve damage. Developed with a novel bispecific antibody design, B2067 produces targeted blockage of NMO-antibody-binding proteins and the complement system’s signaling pathway. There are no similar products on the globe;
(2) On the one hand, B2067 produces competitive inhibition by targeting NMO-autoantibody-binding proteins to reduce attack on the cells from NMO-antibodies. On the other hand, B2067 targets the critical proteins of the complement system’s signaling pathway to block complement system reactions, thereby producing double inhibition.
Next important events and time points
 
It is anticipated that preclinical pharmacodynamics, pharmacokinetics and safety evaluation studies will be initiated in the first quarter of 2022, and an IND application will be filed in the first quarter of 2023.